Antioxidative Hyaluronic Acid–Bilirubin Nanomedicine Targeting Activated Hepatic Stellate Cells for Anti-Hepatic-Fibrosis Therapy
Top Cited Papers
- 30 January 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (6) , 4704-4716
Abstract
Liver fibrosis is a life-threatening and irreversible disease. The fibrosis process is largely driven by hepatic stellate cells (HSCs), which undergo transdifferentiation from an inactivated state to an activated one during persistent liver damage. This activated state is responsible for collagen deposition in liver tissue and is accompanied by increased CD44 expression on the surfaces of HSCs and amplified intracellular oxidative stress, which contributes to the fibrosis process. To address this problem, we have developed a strategy that combines CD44-targeting of activated HSCs with an antioxidative approach. We developed hyaluronic acid-bilirubin nanoparticles (HABNs), composed of endogenous bilirubin, an antioxidant and anti-inflammatory bile acid, and hyaluronic acid, an endogenous CD44-targeting glycosaminoglycan biopolymer. Our findings demonstrate that intravenously administered HABNs effectively targeted the liver, particularly activated HSCs, in fibrotic mice with choline-deficient l-amino acid-defined high-fat diet (CD-HFD)-induced nonalcoholic steatohepatitis (NASH). HABNs were able to inhibit HSC activation and proliferation and collagen production. Furthermore, in a murine CD-HFD-induced NASH fibrosis model, intravenously administered HABNs showed potent fibrotic modulation activity. Our study suggests that HABNs have the potential to serve as a targeted anti-hepatic-fibrosis therapy by modulating activated HSCs via CD44-targeting and antioxidant strategies. This strategy could also be applied to various ROS-related diseases in which CD44-overexpressing cells play a pivotal role.Keywords
Funding Information
- Korea Health Industry Development Institute (RS-2023-00265981)
- Ministry of Education (2021R1A6C101A442, 2023R1A6C103A026)
- National Research Foundation of Korea (2022M3H4A1A03067401, 2022R1C1C1003141, 2018R1A5A2025286)
This publication has 52 references indexed in Scilit:
- An improved mouse model that rapidly develops fibrosis in non‐alcoholic steatohepatitisInternational Journal of Experimental Pathology, 2013
- Hepatocellular ballooning in NASHJournal of Hepatology, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Bilirubin and glutathione have complementary antioxidant and cytoprotective rolesProceedings of the National Academy of Sciences, 2009
- Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosisJournal of Controlled Release, 2008
- Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantationDigestive and Liver Disease, 2005
- Preneoplastic lesions in human hepatocarcinogenesisLiver International, 2005
- Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosisGut, 2004
- Successful Targeting to Rat Hepatic Stellate Cells Using Albumin Modified with Cyclic Peptides That Recognize the Collagen Type VI ReceptorJournal of Biological Chemistry, 2000
- Class Vi Intermediate Filament Protein Nestin Is Induced During Activation of Rat Hepatic Stellate CellsHepatology, 1999